![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » BMS Receives EU Approval for Opdivo Combo for Pleural Mesothelioma
BMS Receives EU Approval for Opdivo Combo for Pleural Mesothelioma
![Bristol Myers Squibb logo](https://www.fdanews.com/ext/resources/test/Drug-Images4/Bristol-Myers-Squibb-logo.gif?t=1599080441&width=430)
The European Commission has granted marketing authorization for Bristol Myers Squibb’s Opdivo (nivolumab) plus Yervoy (ipilimumab) as a first-line therapy for adults with unresectable malignant pleural mesothelioma.
A phase 3 study of more than 600 patients showed that the Opdivo-Yervoy combination increased overall survival vs. chemotherapy (pemetrexed and cisplatin or carboplatin). Patients in the Opdivo-Yervoy arm had a median overall survival of 18.1 months vs. 14.1 months in the chemotherapy cohort.
The Opdivo-Yervoy combination has received previous EU marketing authorizations for other advanced cancers, including nonsmall-cell lung cancer, melanoma and renal cell carcinoma.
Upcoming Events
-
21Oct